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Abstract 
Pancreatic ductal adenocarcinoma (PDAC) is one of the most common causes of cancer-related 
death all over the world. This disease is difficult to treat and patients have an overall 5-year 
survival rate of less than 5%. Although two drugs, gemcitabine (GEM) and 5-fluorouracil (5-FU) 
have been shown to improve the survival rate of patients systematically, they do not increase 
general survival to a clinically acceptable degree. Lack of ideal clinical response of pancreatic 
cancer patients to chemotherapy is likely to be due to intrinsic and acquired chemoresistance of 
tumor cells. Various mechanisms of drug resistance have been investigated in pancreatic cancer, 
including genetic and epigenetic changes in particular genes or signaling pathways. In addition, 
evidence suggests that microRNAs (miRNAs) play significant roles as key regulators of gene 
expression in many cellular processes, including drug resistance. Understanding underlying 
genes and mechanisms of drug resistance in pancreatic cancer is critical to develop new effective 
treatments for this deadly disease. This review illustrates the genes and miRNAs involved in 
resistance to gemcitabine in pancreatic cancer. 
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